Department of Internal Medicine

Infectious Diseases Faculty

Jack Stapleton photo

Medical School:
University of Kansas

Residency:
University of North Carolina

Fellowship:
University of North Carolina


[view PubMed listing]

Jack T. Stapleton, M.D.
Professor
Director, University of Iowa HIV Program
Director, Helen C. Levitt Center for Viral Pathogenesis and Disease

As Director of the University of Iowa HIV clinic, Dr. Stapleton is dedicated to overseeing and providing excellent medical care for people infected with the human immunodeficiency virus (HIV) and/or hepatitis C virus (HCV).  His laboratory research focuses on the interactions between flaviviruses and HIV in vitro and in vivo.  This work originated as epidemiologic and laboratory studies of the effects of co-infection of GB virus type C (GBV-C, a human flavivirus) and HIV, and has expanded to include studies of several other flaviviruses including HCV, Dengue virus and Yellow Fever virus.  In addition, Dr. Stapleton has several clinical studies under way related vaccines (HPV, HSV, smallpox) and to the natural history, management and therapy of HIV, hepatitis C virus, and GBV-C.

Honors, Awards, and Organizations

Links of Interest

Publications

  1. Mohr EL*, Xiang J*, McLinden JH, Kaufman TM, Chang Q, Montefiori DC, Klinzman D, Stapleton JT. GB Virus C envelope protein E2 elicits antibodies that react with a cellular antigen on HIV-1 particles and neutralize diverse HIV-1 isolates. J Immunol, 185:4496-4505, 2010.
  2. The International HIV Controllers Study (including Stapleton JT). The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation. Science, 330:1551-1557, 2010.
  3. Stapleton JT, Foung S, Muerhoff AS, Bukh J, Simmonds P. The GB viruses: A Review and proposed re-classification as Pegiviruses. J Gen Virol, 92:233-246, 2011.
  4. Belshe RB, Leonse PA, Bernstein DI, Wald A, Levin MJ, Stapleton JT, Gorfinkel I, Ashley Morrow RL, Ewell MG, Stokes-Riner A, Dubin G, Heineman TC, Schulte JM, Deal CD, and the Herpevac Trial for Women. Type specific efficacy of herpes simplex virus type 2 glycoprotein D subunit vaccine: Results of the Herpevac Trial for Women. N Engl J Med, 366:34-43, 2012.
  5. Bhattarai N and Stapleton JT. GB virus C: The Good Boy Virus? Trends in Microbiol, 20:123-130, 2012.
  6. Rydze RT, Xiang J, McLinden JH, Stapleton JT. GB virus C infection polarizes T cell cytokine gene expression towards a Th1 cytokine profile via NS5A protein expression. In Press, J Infect Dis, 2012.
  7. Rydze RT*, Bhattarai N*, Stapleton JT. GB virus C infection is associated with a reduced rate of reactivation of latent HIV and protection against activation-induced T cell death. In Press, Antivir Ther, 2012.
  8. Xiang J, McLinden JH, Kaufman TM, Mohr EL, Bhattarai N, Chang Q, Stapleton JT. Characterization of a peptide domain within the GB virus C envelope glycoprotein (E2) that inhibits HIV replication. In Press, Virology, 2012.
  9. Vahidnia F, Stapleton JT, Rutherford GW, Busch M, Custer B, Acquisition of GB virus type C (HGV) and lower mortality in patients with advanced HIV disease. In Press, Clin Infect Dis, 2012.

For additional publications see Dr. Stapleton's PubMed listing.

Patents:

1994 United States Patent No. 5,294,548: Recombinant Hepatitis A Virus Vaccine. McLinden J, Rosen E, Winokur PL, Stapleton JT.
1998 United States Patent No. 5,846,735, 1998: “Hepatitis C Virus Fc Binding Domain” Stapleton, Han, Schmidt, and LaBrecque.
2005 United States Patent No. 6,870,043. "Full-length GB virus C (hepatitis G virus) RNA transcripts are infectious in primary CD4 positive T cells". Xiang J, Wunschmann S, Schmidt WN, Stapleton JT.
2007 United States Patent No. 7,291,723 “GB virus C and methods of treating viral infections”. Stapleton JT, Xiang J, George SL.
2011 United States Patent No. 7,951,531 “Flavivirus NS5A proteins for the treatment of HIV”. Stapleton JT, Xiang J, McLinden JH, Chang Q.

Back to Infectious Diseases Faculty List